NEW YORK (GenomeWeb News) - Investment firm Caris & Company upgraded Illumina's stock to "Buy" from "Above Average" today.
 
The broker cited "removal of Markman ruling overhang" as the reason behind the upgrade.
 
Separately today, investment bank UBS lifted Affymetrix' price target to $20 from $18.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.